Xenotransplantation

Xenotransplantation is the transplantation of living cells, tissues or organs between species. In its modern form it means moving a genetically engineered pig organ into a human, using edits that remove the sugars human antibodies attack and add human proteins that control complement activation and blood clotting. Between 2021 and 2025 the field moved from brain-dead research recipients to living patients under compassionate-use authorisation, and then to formally cleared clinical trials. Every graft so far has failed or been removed within months.

§Why pigs

The driver is arithmetic. More than a hundred thousand people are on the United States transplant waiting list at any time, the great majority waiting for a kidney, and the US Health Resources and Services Administration puts the number dying each day while waiting at around seventeen. Waiting lists understate demand, because patients too sick or too old to qualify are never listed. The structural causes are set out in Organ shortage, and no combination of donation reform, mechanical support and improved organ preservation closes the gap.

Non-human primates are immunologically closer but are slow-breeding, expensive, ethically fraught and carry viruses that cross to humans readily. Pigs breed fast, reach human organ size in months, tolerate genetic modification, and are already farmed at scale. Their organs are anatomically and physiologically similar enough that the remaining mismatches are addressable one gene at a time, which is the premise of the whole enterprise.

§The immunological barrier

Pig organs fail in a human in a defined sequence, and each stage has a corresponding engineering answer.

Hyperacute rejection. Humans have high-titre preformed antibodies against galactose-α-1,3-galactose, a sugar humans and other Old World primates do not make. Within minutes these antibodies fix complement and destroy the graft. Knocking out the GGTA1 gene that installs the sugar eliminates this, and was the first modification made, in the early 2000s. Two further glycans, produced by CMAH and B4GALNT2, are removed for the same reason, giving the "triple-knockout" pig.

Acute humoral rejection. Non-glycan antibodies and residual complement activity damage the graft over days to weeks. Human complement regulatory proteins CD46 and CD55 are added as transgenes to hold this in check, alongside CD47 to reduce macrophage attack and heme oxygenase-1 to limit oxidative injury.

Coagulation dysregulation. Pig thrombomodulin activates human protein C poorly, so the graft endothelium fails to restrain clotting and thrombotic microangiopathy develops. Human thrombomodulin and endothelial protein C receptor are added to correct the molecular mismatch. This is the barrier least amenable to conventional immunosuppression and the one that most distinguishes xenografts from allografts.

Physiological mismatch. Pig organs grow to pig proportions. Knocking out the growth hormone receptor limits this. Other mismatches, in erythropoietin signalling and in the renin-angiotensin system, are managed pharmacologically rather than genetically.

Two engineering strategies have emerged. Revivicor's animals carry ten modifications, four knockouts and six human transgenes. eGenesis, founded out of George Church's laboratory, adds inactivation of the porcine endogenous retrovirus copies scattered through the pig genome, giving sixty-nine total edits. The PERV work grew out of demonstrations that dozens of retroviral copies could be knocked out at once in pig cells and then in live piglets, an early proof that CRISPR–Cas9 could be used at the edit counts previously seen only in the genome-recoding work on bacteria.¹² The same multiplex capability underlies the proxy-species programmes described in De-extinction, and pigs are the animal in which it has been pushed furthest toward a product.

§Development history

1. 1963–1964
   Primate era
   Keith Reemtsma transplants chimpanzee kidneys, one recipient surviving nine months, and James Hardy places a chimpanzee heart in a dying patient. Immunology of the day cannot sustain the grafts.
2. 1984
   Baby Fae
   An infant with hypoplastic left heart syndrome receives a baboon heart at Loma Linda and lives 21 days. The case prompts lasting debate about consent and about experimental surgery in neonates.
3. 2003
   Alpha-gal knockout pigs
   Pigs lacking GGTA1 are produced, removing the antigen responsible for hyperacute rejection and making the modern programme possible.
4. 2018
   Preclinical durability
   A Munich group reports baboons surviving for months on life-supporting pig hearts using non-ischaemic preservation and blood-pressure control, establishing that the model can work.
5. 2021–2023
   Decedent studies
   Teams at NYU and Alabama transplant pig kidneys into brain-dead recipients maintained on ventilators, one for 61 days, to study early function without risk to a patient.
6. 2022–2025
   Living recipients
   Two pig hearts and several pig kidneys are transplanted under compassionate-use rules, with survival measured in weeks to months, and US regulators clear the first formal kidney trials in 2025.

§Clinical experience

The preclinical foundation is stronger than the clinical record. Pig hearts have supported baboons for periods measured in months rather than days once preservation and perioperative management were optimised.³ Humanised pig kidneys have supported cynomolgus monkeys for many months, with individual animals surviving beyond a year.⁴

In humans the record is short. David Bennett Sr. received a ten-gene pig heart at the University of Maryland in January 2022 and survived about two months; the graft showed diffuse damage, and porcine cytomegalovirus DNA was detected in his circulation, raising the possibility that an incompletely screened donor virus contributed.⁵ A second Maryland heart recipient in 2023 survived roughly six weeks. Kidney recipients have done somewhat better: a Massachusetts General Hospital patient received a sixty-nine-edit kidney in March 2024, and an Alabama patient's kidney at NYU functioned about four months before it was removed in 2025, the longest such graft reported. Earlier work in brain-dead recipients had shown that a pig kidney makes urine and clears creatinine in a human circulation.⁶

Every recipient so far has been ineligible for a human organ, which is what made the risk-benefit calculation defensible and also what makes the results hard to interpret. These are severely ill patients on experimental immunosuppression, often including costimulation blockade agents not approved for transplantation.

§Infection, welfare and consent

Cross-species infection is the risk that extends beyond the patient. Porcine endogenous retroviruses are integrated in the pig genome and cannot be bred out, which is why eGenesis inactivates them; a long-term follow-up of patients exposed to living pig tissue in extracorporeal treatments found no evidence of transmission, which is reassuring but not decisive for whole-organ grafts under immunosuppression.⁷ Exogenous viruses have proved the more immediate problem, as the porcine cytomegalovirus finding in the first heart recipient showed. Donor animals are therefore raised in designated pathogen-free facilities with barrier housing and repeated screening, and recipients are enrolled in indefinite surveillance.

That surveillance carries an unusual consent structure. A xenograft recipient accepts lifelong monitoring, restrictions on blood and tissue donation, and in some protocols obligations extending to close contacts, on grounds of public health rather than personal benefit. Regulators have generally required this, and it is one of the few areas of medicine where a patient's autonomy is curtailed to protect third parties.

Animal welfare is the standing objection. Donor animals are produced by the nuclear-transfer methods described in Human cloning, raised in isolation, and killed on a surgical schedule. Defenders point out that pigs are farmed for food in vastly greater numbers under less controlled conditions; critics reply that instrumental use for organs invites a scale of purpose-bred confinement that food production does not justify by analogy. Religious authorities in traditions that restrict pork have generally permitted xenotransplantation where life is at stake.

Bridge or destination

One reading treats pig organs as a bridge, keeping patients alive until Lab-grown organs, Organ bioprinting or the reseeded matrix scaffolds of Tissue engineering mature. Another treats them as the destination, on the argument that growing a vascularised human kidney from Induced pluripotent stem cells remains far harder than editing a pig, and that a manufacturable animal organ is the realistic supply solution for this century.

§Outlook

The decisive data should come from the cleared kidney trials, where recipients are less critically ill than the compassionate-use cohort and where survival can be compared against dialysis rather than against imminent death. The endpoint that matters is graft function at one year. Nothing in the human record yet approaches it, and the preclinical primate data suggest it is attainable.

Three questions remain open. Whether the coagulation mismatch is fully corrected by the current transgene set, or merely delayed, will only be answered by grafts that survive long enough to develop chronic injury. Whether immunosuppression can be reduced to allograft-like levels, rather than the intensive experimental regimens used so far, determines whether the treatment is tolerable for patients who have a dialysis alternative. And whether a manufactured organ produced by a small number of firms is distributed any more equitably than donated ones is a question that the technology does not answer and that Access and inequality raises for every expensive intervention.

§See also

• Organ shortage
• Lab-grown organs
• Organ bioprinting
• Decellularized scaffolds
• CRISPR–Cas9
• De-extinction
• George Church
• Artificial heart

§References